Back to results
US 2010/0137212 A1Published application
Use of glp-1 receptor agonists for the treatment of gastrointestinal disorders
AssigneeCedars-Sinai Medical Center
InventorsMark Pimentel, Edy E. Soffer, Jeffrey Conklin
Life of this patent
Estimating the term…
Abstract
The present invention describes the methods of using incretin mimetics such as GLP-1 receptor agonists, particularly exenatide, to treat short bowel syndrome and spastic or hyperactive esophageal motor disorders.
Claims28
A method for treating a gastrointestinal disorder in a subject in need thereof, comprising:
- providing an incretin mimetic;
- and
- administering a therapeutically effective amount of the incretin mimetic to the subject.
A method of normalizing bowel function in a subject in need thereof, comprising:
- providing an incretin mimetic;
- and
- administering a therapeutically effective amount of the incretin mimetic to the subject.
A kit for treating a gastrointestinal disorder in a subject in need thereof, comprising:
- an incretin mimetic;
- and
- instructions to administer a therapeutically effective amount of the incretin mimetic to the subject.
Dependencies are inferred from the claim text.